Discovery of (phenylureido)piperidinyl benzamides as prospective inhibitors of bacterial autolysin E from Staphylococcus aureus

Jure Borisiča, Sara Pintarh,i, Mitja Ogrizeka, Simona Golič Grdadolnič, Vesna Hodnikd, Dušan Turkh,⁎,Andrej Perdiha and Marjana Novicb

aNational Institute of Chemistry, Ljubljana, Slovenia; bDepartment of Biochemistry, Molecular and Structural Biology, Jozef Stefan Institute, Ljubljana, Slovenia; cJozef Stefan International Postgraduate School, Ljubljana, Slovenia; dBiotechnical Faculty, Infrastructural Center for Surface Plasmon Resonance, Ljubljana, Slovenia; eCentre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, Ljubljana, Slovenia

Abstract

Autolysin E (AtlE) is a cell wall degrading enzyme that catalyzes the hydrolysis of the β-1,4-glycosidic bond between the \textit{N}-acetylglucosamine and \textit{N}-acetylmuramic acid units of the bacterial peptidoglycan. Using our recently determined crystal structure of AtlE from \textit{Staphylococcus aureus} and a combination of pharmacophore modeling, similarity search, and molecular docking, a series of (Phenylureido)piperidinyl benzamides were identified as potential binders and surface plasmon resonance (SPR) and saturation-transfer difference (STD) NMR experiments revealed that discovered compounds bind to AtlE in a lower micromolar range. (phenylureido)piperidinyl benzamides are the first reported non-substrate-like compounds that interact with this enzyme and enable further study of the interaction of small molecules with bacterial AtlE as potential inhibitors of this target.

Introduction

In the last decade resistance to antibiotics and other antimicrobial compounds became a global problem with increasing importance. One of the promising strategies to confront aforementioned challenge is to investigate new antibiotic targets aiming at discovery of new classes of antibiotics. In particular, remodeling and hydrolysis of cell wall remains largely unexploited territory as opposed to widely explored area of targeting peptidoglycan synthesis pathways. Autolysin E (AtlE) from \textit{Staphylococcus aureus} is one of the peptidoglycan degrading enzymes and its inhibition could pave the way to potential novel class of antimicrobial agents.

\textit{Staphylococcus aureus} is a widespread gram-positive pathogen of humans and animals. In most cases, it lives as a commensal organism on the skin and mucous membranes and poses no threat to healthy individuals. However, when it enters into the body through breaches in skin or membranes, it may pose a serious risk especially for immunocompromised individuals. It can cope with hostile conditions encountered in the bloodstream of the living host, a scarce supply of certain nutrients, attacks of the immune system and anti-infective measures undertaken in the clinical field. List of infections it causes includes bacteremia, infective endocarditis, impetigo, surgical site infections, cutaneous abscesses, purulent cellulitis, osteomyelitis, septic arthritis, prothetic device infections, and toxic shock syndrome. Another feature that makes it even more difficult to treat is its ability to form biofilm. Biofilm is a community of microorganism that is attached to the surface and plays a significant role in persistence of bacterial infections. Bacteria within biofilms are several orders of magnitude more resilient to antibiotics, compared with planktonic bacteria. The huge repertoire of different virulence factors and additional supportive gene products that increase its capability to survive within the living host make \textit{S. aureus} one of the most threatening microorganisms causing hospital and community-acquired infections.

Wide-spread use of antibiotics in recent decades has resulted in emergence of antibiotic and multiple antibiotic resistant strains, such as methicillin (MRSA) and vancomycin resistant \textit{S. aureus}. Before 1980s MRSA was considered a healthcare-associated disease, however there has been a dramatic increase in the number of community-based infections due to it. For most of the known antibiotics, strains resistant to each, have been isolated. The threat of the spread of even more resistant \textit{S. aureus} strains urges the development of new antibiotics targeting this organism.

The genome of \textit{S. aureus} strain Mu50 codes for five \textit{N}-acytelyglucosaminidases, one of them being AtlE, which belongs to the glycoside hydrolases (GH) 73 family. During growth and division bacteria have to synthesise and degrade peptidoglycan. Cells with inactivated \textit{N}-acytelyglucosaminidases have morphological defects as a consequence of impaired ability to increase in size after division and adopt correct mature shape. Further it has been shown that some autolysins have a role in concealing bacteria from the receptor proteins that detect peptidoglycan and thus enable the pathogen to evade the immune system of the host. Therefore, enzymes involved in the cell wall degradation can be considered as novel, valuable extracellular drug/vaccine targets. It may seem at a first glance contradictory that blocking the enzyme

CONTACT Marjana Novic, marjana.novic@ki.si
National Institute of Chemistry, Hajdrihova 19, SI-1001, Ljubljana, Slovenia.

ARTICLE HISTORY
Received 4 June 2018
Revised 22 June 2018
Accepted 22 June 2018

KEYWORDS
Autolysin E; glycoside hydrolase; virtual screening; SPR; STD NMR
responsible for the degradation of the bacterial cell wall would have antimicrobial effect. However, as described above, the bacteria needs to degrade peptidoglycan in certain stages of growth and division, thus the inhibition of such enzymes would be beneficial. Interestingly, also an alternative molecular engineering approach was developed to enhance the bacteriolytic activity of autolysins and thus make them promising antimicrobial agents.  

AtlE from *S. aureus* is an enzyme from the GH73 family. In our previous studies, the crystal structure of AtlE and its structures with fragments of its substrate have been determined and thereby the binding groove for the substrate has been experimentally identified. AtlE has a binding site that can accommodate three NAG-NAM units of its natural peptidoglycan substrate and cleaves the β-1,4-glycosidic bond between the N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM). Furthermore, active site residue Glu138 was confirmed as crucial for the activity of the enzyme (Figure 1).  

In order to discover AtlE inhibitors, several computational structure-based drug design tools were employed. Binding affinities of the most promising virtual hits obtained by iterative processes of pharmacophore modeling, similarity search and molecular docking were determined experimentally using surface plasmon resonance (SPR) and saturation-transfer difference (STD) NMR experiments.

Materials and methods  
Investigation of the AtlE binding site and pharmacophore-based virtual screening experiments  
In order to determine the starting point for the virtual screening, experimentally remodeled AtlE substrate was derived from previous study. As remodeled AtlE substrate contains 3 (NAG-NAM) units, we focused on the central NAG-NAM unit being bound near the catalytic Glu138 residue. The remodeled substrate structure of the NAG-NAM unit in the AtlE binding site (PDB ID: 4PIA) was used to explore interactions using LigandScout software and to derive structure-based pharmacophore for the NAG-NAM ligand (see Figure 1). The pharmacophore model was used to screen approximately 5 million commercially available compounds, all of which were previously converted into multifunctional format (25 conformers for each compound in the database) using the LigandScout screening module. The conformers of the molecules in the screening library were generated using the idbgen module available in LigandScout, coupled with the OMEGA software. The default high-throughput settings were used for the library generation: maximum number of output conformers per molecule = 25; RMS threshold to duplicate conformers = 0.8 Å; maximum number of all generated conformers per molecule = 30,000; and maximum...
number of intermediate conformers per molecule = 4000. Pharmacophore Fit scoring function was used to score the matching of the hit molecules to the pharmacophore model. The LigandScout screening procedure retrieved approximately 10,000 hit compounds that were subsequently docked in the AtlE binding site.

**Molecular docking calculations**

Molecular docking studies were performed using GOLD Suite v5.1 docking package. Binding site was defined around remodeled substrate coordinates of the NAG-NAM ligand in radius of 12 Å. Validation of the docking settings was performed by redocking of the NAG-NAM ligand of the remodeled substrate into the AtlE binding site. The observed RMSD of obtained docked poses versus the original NAG-NAM position were within the accepted limits of 1.1 ppm. The final immobilization level was about 4100 RU. Screening was tested at eight different concentrations (depending on their solubility) in three parallel titrations. KD values were determined by fitting of the data to a 1:1 steady state binding model.

**Surface plasmon resonance (SPR) experiments**

SPR experiments were performed using a Biacore T100 (GE Healthcare) equipped with a Series S sensor chip CM5 (GE Healthcare). PBS buffer (67 mM Na2HPO4, 12.5 mM KH2PO4, 70 mM NaCl, 0.05% P20, pH 7.4) was used for immobilisation of the protein. AtlE was produced as previously described and attached to the surface of the chip by amine coupling. The surface of flow cells 1 and 2 was initially activated with a 10-min pulse of a 1:1 mixture of 0.4 M 1-ethyl-3-[(3-dimethylaminopropyl)-carbodiimide hydrochloride and 0.1 M N-hydroxysuccinimide, according to manufacturer recommendations. AtlE was diluted into 10 mM sodium acetate buffer, pH 5.8, to a final concentration of 100 µg/mL, and injected twice for 180 s over the second flow cell. Both flow cells were blocked with a 7-min pulse of 1.0 M ethanolamine. The final immobilisation level was about 4100 RU. Screening was run at 25 °C using PBS (67 mM Na2HPO4, 12.5 mM KH2PO4 pH 7.4, 70 mM NaCl, 0.05% P20) supplemented with 1% or 5% DMSO (Merck) as the running buffer. Selected compounds from the virtual screening studies were tested at two different concentrations: 30 and 400 µM. Each compound was injected for 1 min at a flow-rate of 30 µL/min, and the dissociation was monitored for 30 s. Regeneration was not needed, although 30 s of buffer-flow was used to stabilise the surface after each injection. We compared the responses obtained by the injections of the buffer and the two different sample concentrations, and continued the study with the compounds that showed binding. Selected compounds were tested at eight different concentrations (depending on their solubility) in three parallel titrations. KD values were determined by fitting of the data to a 1:1 steady state binding model.

**DirectDrive 800 MHz spectrometer at 25 °C. All data were collected using pulse sequences and phase-cycling routines provided in Varian libraries of pulse programs. The cryogenic triple-resonance NMR probe was used. NMR samples were prepared in a buffer containing 20 mM Tris-D11, 10% glycerol-D8, and 100 mM NaCl in D2O, pH 7.2. DSS (0.1 mM) was used as an internal standard. All the spectra were recorded at a protein/ligand ratio of 1:100, the protein concentration was 1 µM and the ligand concentration was 0.1 mM. The STD experiments were performed with a 8802.8 Hz spectral width, 16384 data points, a saturation time of 2 s, a relaxation delay of 1.3 s, and 3800 scans. Selective saturation was achieved by a train of 50 ms long Gauss-shaped pulses separated by 1 ms delay. Water was suppressed via excitation sculpting. The on-resonance selective saturation of AtlE was applied at −0.9 ppm, which is well separated from the methyl group of compounds at 1.1 ppm. The off-resonance irradiation was applied at 30 ppm for the reference spectrum. Subtraction of the on and off-resonance spectra was performed internally via phase cycling. Spectra were zero-filled twice and apodised by an exponential line-broadening function of 1 Hz.

**Results and discussion**

**Design phase I: virtual screening**

To identify AtlE inhibitors, our design starting point were the available structural information of the enzyme AtlE (PDB ID: 4PIA) and its remodeled substrate from our previous study. Briefly, the substrate model in the active site cleft of AtlE was constructed by merging information from substrate fragments of superimposed complexes of AtlE and G-type lysozyme (PDB IDs: 4PI7, 4PI9, 3GXR and 148L). The AtlE substrate model contained 3 NAG-NAM units. The central unit NAG–1–NAM +1 representing the cleavage site was positioned next to the catalytic Glu138 residue. This disaccharide unit was selected to derive structure based pharmacophore for the initiation of the virtual screening campaign and remodeled using ligands NAG and MUB from the complexes 3GXR and 148L, respectively. The AtlE substrate model was used in a large scale virtual screening campaign

(a) and remodeled using ligands NAG and MUB from the complexes 3GXR and 148L, respectively (Figure 1(b)). It contained the interaction pattern with the AtlE based on hydrogen bonds with Gly162, Ser226, Asp227 and Lys233.

To identify molecules that retained molecular recognition pattern of the selected NAG-NAM unit, several in silico techniques were employed as powerful drug design tools. First, a structure-based pharmacophore model mimicking the interactions of the selected central NAG-NAM unit with the AtlE binding site was generated using LigandScout software. Pharmacophores consisted of the following features: hydrogen bond acceptor (describing the interaction with the Gly162) and three hydrogen bond donors (observed with Ser226, Ser227 and Lys233) (Figure 1). Exclusion volume spheres were also derived, mimicking the sterical boundary conditions of the AtlE-binding site. Interaction between scissile glycosidic substrate bond and Glu138 was not identified by LigandScout as potential H-bond pharmacophore feature due to not optimal geometry. This is in accordance with our previous MD simulations of the AtlE bound with (NAG-NAM)3 substrate which have suggested a complex role of Glu138 residue in molecular recognition and catalysis.

In order to broaden the chemical space of the resulted virtual hits, we introduced an additional criterion that three out of initial four pharmacophore features had to be satisfied for a compound to be considered as a hit. Subsequently, this pharmacophore model was used in a large scale virtual screening campaign, using available library of approximately 5 million commercially available compounds. This procedure resulted in approximately 10,000 virtual hits from different structural classes that were able to comply with the requested pharmacophore features.

Hits obtained were subsequently docked into the AtlE binding site using the GOLD molecular docking tool (see Experimental
section for GOLD parameter settings) to explore the proposed orientations of these molecules. A successful validation of the docking model was made by redocking of the NAG-NAM molecule in the substrate binding groove. The investigated binding site was defined as a 12 Å spherical cavity around ligand NAG-NAM coordinates. The docking procedure was performed by applying the ChemPLP scoring function, and top 200 ranked docking solutions by scoring function were visually inspected for the fitness and orientation in the AtlE binding site. We were aware that scoring fitness function approach beared certain inherent limitations such as accurate ranking of docking solutions for an investigated ligand and adequate description of entropic contributions. Since

| Compound | Structure | $K_d$ (µM) | Compound | Structure | $K_d$ (µM) |
|----------|-----------|------------|----------|-----------|------------|
| 1        | ![Compound 1](image1.png) | $>1000$    | 6        | ![Compound 6](image6.png) | $>1000$    |
| 2        | ![Compound 2](image2.png) | $>1000$    | 7        | ![Compound 7](image7.png) | $>1000$    |
| 3        | ![Compound 3](image3.png) | 177        | 8        | ![Compound 8](image8.png) | $>1000$    |
| 4        | ![Compound 4](image4.png) | $>1000$    | 9        | ![Compound 9](image9.png) | $>1000$    |
| 5        | ![Compound 5](image5.png) | $>1000$    |          |           |            |

Most promising hit 3 marked in gray.
Table 2. Compounds from the structural class of (phenylureido)piperidinyl benzamides tested for AtlE binding affinity in SPR experiments.

| Compd | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | R<sup>4</sup> | $K_d$ (µM) |
|-------|----------------|-------------|-------------|-------------|-----------|
| 10    | -H             | -Cl         |             |             | 1.9       |
| 11    | -Me            | -H          | -H          |             | 2.4       |
| 12    | -H             | -Cl         | -H          |             | 2.5       |
| 13    | -Me            | -H          | -H          | -H          | 6.1       |
| 14    | -Me            | -H          | -H          | -H          | 11.3      |
| 15    | -Me            | -H          |             | -H          | 11.7      |
| 16    | -Me            | -H          | -H          |             | 18.2      |
| 17    | -H             | -H          | -H          |             | 21.1      |
| 18    | -Me            | -H          |             | -Et         | 38.8      |
| 3     | -H             | -H          |             |             | 177       |

(continued)
no ligands are known for this target, we decided to utilise this option as selection criteria. There are cases in the literature that support the potential of this approach. Finally, 41 compounds from different structural classes were selected from the pool of approximately 200 hits by applying previously derived criteria of fitness, orientation and scoring function, and their binding affinities to AtlE was determined using SPR (see Supplementary Table 1). In the first design phase, several compounds from the diverse structural classes exhibited binding affinity in millimolar range ($K_d > 1000 \text{mM}$) Table 1. 

We were especially pleased to observe that compound 3 from the structural class of (phenylureido)piperidinyl benzamides was found to exhibit promising binding affinity to AtlE in the micromolar range (see Figure 1(c) and Figure S1c for SPR sensorgram of 3) making it to the best of our knowledge the first identified reported compound that binds this target.

To gain an insight into the molecular recognition of 3 by AtlE molecular docking was applied. A binding mode suggested hydrogen bonds with AtlE residues Gly162, Tyr224, Ser226 and Asp227, hydrophobic interactions with Phe63 and Tyr201, and electrostatic cation-Pi interaction with Lys233 (Figure S1).

**Design phase II: screening and evaluation of a (phenylureido)piperidinyl benzamides focused library**

The first phase of our VS campaign, described in Design Phase I, yielded a promising micromolar AtlE ligand, to the best of our knowledge the first ever described small molecule binder for this target. In order to provide initial SAR a focused library of all commercially available, (phenylureido)piperidinyl benzamides was extracted from the eMolecules library. It consisted of 16 molecules (10–25), which were tested for their binding affinity to AtlE by SPR. None of these molecules were present in our initial library of screened compounds. The results of the SPR binding affinity assay are presented in Table 2; SPR sensorgrams for active compounds are shown in Figure S2.

Additionally, SPR experiments revealed fast and tight binding to the AtlE at low micromolar concentrations. All commercially available compounds possessing AtlE binding affinity were

---

**Table 2. Continued.**

| Compd | $R^1$ | $R^2$ | $R^3$ | $R^4$ | $K_d$ ($\mu$M) |
|-------|-------|-------|-------|-------|---------------|
| 19    | -Me   | -H    |       | -H    | $>1000$       |
| 20    | -Me   | -H    |       | -Me   | $>1000$       |
| 21    | -H    | -H    |       |       | $>1000$       |
| 22    | -H    | -H    |       | -Et   | $>1000$       |
| 23    | -Me   | -H    |       | -H    | $>1000$       |
| 24    | -H    | -H    |       | -H    | $>1000$       |
| 25    | -Me   | -H    |       |       | $>1000$       |
Figure 2. Hydrophilic and hydrophobic regions of AtlE binding surface for modeled compound 10 are depicted in blue and yellow, respectively. Hydrophobic region R1, R2 and R3, R4 represent the area where substituents of (phenylureido)piperidinyl benzamides R1 and R2, and R3, R4 bind, respectively.

Figure 3. Proposed interaction binding pattern between the active (phenylureido)piperidinyl benzamides compound 10 and the AtlE binding site based on molecular docking calculations, depicted in (a) 2D and (b) 3D. It comprises two hydrogen bond acceptors (Gly162 and Tyr224), two hydrogen bond donors (Ser226 and Asp227), several hydrophobic interactions with Phe63, Val137, Ile163, and Phe196 and Lys233 electrostatic cation–Pi interaction. Green residue represents hydrogen bond acceptor, red residues hydrogen bond donors, black residues form hydrophobic interactions and magenta residue forms electrostatic cation–Pi interaction.
characterised for their identity by HR-MS techniques (see Supplementary Information).

Our further SPR measurements of the focused library yielded additional nine compounds with the binding affinity to AtlE in the low micromolar range from the same structural class of (phenylureido)piperidinyl benzamides (Table 2). This enabled rough estimation of SAR properties required for binding to this target.

Based on the binding affinities and on the molecular docking calculations of compounds 3, 10 and 16, we concluded that the chlorine substituent at the R2 position is the most important for binding affinity as the R1 methyl containing 16 has 10 times lower affinity (Kd = 18.2 µM) and R1, R2 non-substituted 3 (Kd = 177 µM) has 100 times lower affinity than 10 (Kd = 1.9 µM), respectively. We could hypothesise that R1 and R2 substituents bind into the hydrophobic region of AtlE-binding site comprising Ile163, Tyr177, Phe196 and Tyr201 residues (Figures 2 and 3).

Compounds with cyclic lipophilic/ aromatic fragments on the R3 and/or the R4 display a higher affinity (Kd = low µM range) than compounds 22, 23, 24 (Kd > 1000 µM) with alkyl fragments on the R3 and/or R4 positions. The models suggested that the substituents on the R3 and/or R4 positions bind into the elongated hydrophobic region, comprised by Phe63, Val137, and Trp230 residues and also might form additional electrostatic interactions with Glu138 and Lys233. Most of the active (phenylureido)piperidinyl benzamides compounds form hydrogen bonds with Gly162, Gly164, Tyr224, Ser226 and Asp227.

Binding model of the ligands in AtlE binding site based on the molecular docking calculations was similar for all the (phenylureido)piperidinyl benzamides compounds. It is schematically presented for the model compound 10 (Figure 3).

The AtlE substrate binding site is quite extensive as it can accommodate the substrate with six aminosugar NAG-NAM units. Thus alternative binding modes seemed also possible for the relatively small molecule as 10. Nevertheless, the interaction binding pattern of compound 10 was well defined. It comprised two hydrogen bonds acceptors (Gly162 and Tyr224), two hydrogen bond donors (Ser226 and Asp227), and several hydrophobic interactions with Phe63, Val137, Ile163, and Phe196 and Lys233 electrostatic cation–π interaction. Compared to the initial structure-based pharmacophore for the NAG-NAM (see Figure 1), 10 retained the binding pattern of one hydrogen bond donor (Gly162) and two hydrogen bond acceptors (Ser226 and Asp227).

We unsuccessfully attempted to perform enzymatic assays due to poor compounds solubility. In order for this assays to be successful the concentration of the inhibitor needs to be above its solubility in used assay settings. However, (phenylureido)piperidinyl benzamide are the first known series of non-substrate-like compounds thus represent the first reported non-substrate like compounds that interact with this bacterial target with shown direct binding data obtained by two independent biophysical experiments. Thus, these compounds offer promise to pave the way to the first hit compounds of this cell wall degrading enzyme and enable its validation as drug target.

Disclosures
No potential conflict of interest was reported by the authors.

Funding
The authors acknowledge the financial support from the Slovenian Research Agency [research core funding No. P1–0017, P1–0012, P1–0048 and J1-8145].

References
1. Rossolini GM, Arena F, Pecile P, et al. Update on the antibiotic resistance crisis. Curr Opin Pharmacol 2014;18:56–60.
2. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529:336–343.
3. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 2010;8:423–435.
4. Mihelic M, Vlahovic-Kahлина K, Renko M, et al. The mechanism behind the selection of two different cleavage sites in nag-nam polymers. IUCR 2017;4:185–198.
5. Kulhankova K, King J, Salgado-Pabon W. Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol Res 2014;59:182–187.
6. Kulkova K, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28:603–661.
7. Mancl KA, Kirsner RS, Ajdic D. Wound biofilms: lessons learned from oral biofilms. Wound Repair Regen 2013;21:352–362.
8. Rabin N, Zheng Y, Opoku-Temeng C, et al. Biofilm formation mechanisms and targets for developing antibiotic agents (vol 7, pg 493, 2015). Future Med Chem 2015;7:493–1362.
9. Rosenstein R, Gotz F. What distinguishes highly pathogenic staphylococci from medium- and non-pathogenic? Betw Pathogen Commensal 2013;358:33–89.

10. Knox J, Uhlemann A-C, Lowy FD. Staphylococcus aureus infections: transmission within households and the community. Trends Microbiol 2015;23:437–444.

11. Xia JF, Gao JJ, Kokudo N, et al. Methicillin-resistant Staphylococcus aureus antibiotic resistance and virulence. Biosci Trends 2013;7:113–121.

12. Wheeler R, Turner RD, Bailey RG, et al. Bacterial cell enlargement requires control of cell wall stiffness mediated by peptidoglycan hydrolases. Mbio 2015;6:e00660–15.

13. Chan YGY, Frankel MB, Missiakas D, Schneewind O. Sagbin glucosaminidase is a determinant of Staphylococcus aureus glycan chain length, antibiotic susceptibility, and protein secretion. J Bacteriol 2016;198:1123–1136.

14. Atilano ML, Pereira PM, Vaz F, et al. Bacterial autolysins trim cell surface peptidoglycan to prevent detection by the drosophila innate immune system. Elife 2014;3:e02277.

15. Osipovitch DC, Therrien S, Griswold KE. Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity. Appl Microbiol Biotechnol 2015;99:6315–6126.

16. Lombard V, Ramulu HG, Drula E, et al. The carbohydrate-active enzymes database (cazy) in 2013. Nucleic Acids Res 2014;42:D490–D495.

17. Borisek J, Pintar S, Ogrizek M, et al. water-assisted catalytic mechanism in glycoside hydrolases demonstrated on the Staphylococcus aureus autolysin e. ACS Catal 2018;8:4334–4345.

18. Wolber G, Langer T. Ligandscout: 3-d pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Infomat Model 2005;45:160–169.

19. Skedelj V, Perdih A, Brvar M, et al. Discovery of the first inhibitors of bacterial enzyme d-aspartate ligase from Enterococcus faecium (asl(fm)). Eur J Med Chem 2013;67:208–220.

20. Hawkins PCD, Skillman AG, Warren GL, et al. Conformer generation with omega: algorithm and validation using high quality structures from the protein databank and cambridge structural database. J Chem Infomat Model 2010;50:572–584.

21. Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using gold. Proteins 2003;52:609–623.

22. Kirchmair J, Markt P, Distinto S, et al. Evaluation of the performance of 3d virtual screening protocols: Rmsd comparisons, enrichment assessments, and decoy selection - what can we learn from earlier mistakes?. J Comput Aided Mol Design 2008;22:213–228.

23. Mayer M, Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed Engl 1999;38:1784–1788.

24. Helland R, Larsen RL, Finstad S, et al. Crystal structures of glycoype lysozyme from atlantic cod shed new light on substrate binding and the catalytic mechanism. Cell Mol Life Sci 2009;66:2585–2598.

25. Kuroki R, Weaver LH, Matthews BW. A covalent enzyme-substrate intermediate with saccharide distortion in a mutant t4 lysozyme. Science 1993;262:2030–2033.

26. Korb O, Stutzle T, Exner TE. Empirical scoring functions for advanced protein-ligand docking with plants. J Chem Infomat Model 2009;49:84–96.

27. Liebeschuetz JW, Cole JC, Korb O. Pose prediction and virtual screening performance of gold scoring functions in a standardized test. J Comput Aided Mol Des 2012;26:737–748.

28. Brus B, Kosak U, Turk S, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014;57:8167–8179.

29. Database emolecules. http://www.emolecules.com/.

30. Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins Structure Funct Bioinform 2006;65:15–26.

31. Viegas A, Manso J, Nobrega FL, et al. Saturation-transfer difference (std) NMR: a simple and fast method for ligand screening and characterization of protein binding. J Chem Educ 2011;88:990–994.